LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Akcijų sąrašas・Innoviva Inc

Innoviva Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

22.45 1.35

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

22.2

Max

22.49

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-55M 187M
Pardavimai	-20M 98M
P/E Sektoriaus vid.	3.482 49.701
Pelnas, tenkantis vienai akcijai	0.468
Pelno marža	190.415
Darbuotojai	159
EBITDA	-160M 48M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+54.05% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-04

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-93M 1.6B
Ankstesnė atidarymo kaina	21.1
Ankstesnė uždarymo kaina	22.45

Naujienos nuotaikos

By Acuity

50%

151 / 345 reitingas Healthcare

Innoviva Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-24 23:46; UTC

Rinkos pokalbiai

Pullback in Oil Prices Could Temper Inflation Expectations -- Market Talk

2026-05-24 23:45; UTC

Rinkos pokalbiai

Gold, Silver Rise on Hopes for U.S.-Iran Deal -- Market Talk

2026-05-24 23:42; UTC

Rinkos pokalbiai

Mineral Resources Bull More Positive Post Site Visit -- Market Talk

2026-05-24 23:34; UTC

Rinkos pokalbiai

Oil Falls Amid Prospects for Reopening of Strait of Hormuz -- Market Talk

2026-05-24 23:11; UTC

Rinkos pokalbiai

RBNZ Likely to Stand Pat But Watch for Dissent -- Market Talk

2026-05-24 22:26; UTC

Įsigijimai, susijungimai, perėmimai

Beach Energy: La Bella 2 Will No Longer Be Drilled as Part of Equinox Campaign

2026-05-24 22:25; UTC

Įsigijimai, susijungimai, perėmimai

Beach Energy: Implied Transaction Value of Around A$130 Million After Tax

2026-05-24 22:25; UTC

Įsigijimai, susijungimai, perėmimai

Beach Energy: Royalty Payments Likely to Total Around A$140 Million Based on Resource Booking

2026-05-24 22:24; UTC

Įsigijimai, susijungimai, perėmimai

Beach Energy to Get Production Royalty of A$3.75/GJ in Deal

2026-05-24 22:24; UTC

Įsigijimai, susijungimai, perėmimai

Beach Energy to Get A$70 Million Cash Proceeds When Deal Completes

2026-05-24 22:23; UTC

Įsigijimai, susijungimai, perėmimai

Beach Energy Says Deal Includes Artisan Natural-Gas Discovery

2026-05-24 22:23; UTC

Įsigijimai, susijungimai, perėmimai

Beach Energy Sells 60% Operated Interest in VIC/L35 Block in Otway Basin

2026-05-24 22:11; UTC

Rinkos pokalbiai

Oil Price Unlikely to Return to Pre-Conflict Levels This Year -- Market Talk

2026-05-24 22:04; UTC

Rinkos pokalbiai

Oil Price Likely Lower, Equities Higher on Iran Deal Talks Progress -- Market Talk

2026-05-23 08:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-05-23 08:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-22 21:10; UTC

Uždarbis

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

2026-05-22 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-22 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-05-22 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-22 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-22 19:47; UTC

Uždarbis

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

2026-05-22 19:17; UTC

Rinkos pokalbiai

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

2026-05-22 19:10; UTC

Rinkos pokalbiai

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

2026-05-22 18:54; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-22 18:54; UTC

Rinkos pokalbiai

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

2026-05-22 18:38; UTC

Rinkos pokalbiai

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

2026-05-22 18:35; UTC

Įsigijimai, susijungimai, perėmimai

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

2026-05-22 18:09; UTC

Rinkos pokalbiai

Centralized Crypto Lending Slows in 1Q -- Market Talk

2026-05-22 17:58; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

Akcijų palyginimas

Kainos pokytis

Innoviva Inc Prognozė

Kainos tikslas

By TipRanks

54.05% į viršų

12 mėnesių prognozė

Vidutinis 34.6 USD 54.05%

Aukščiausias 46 USD

Žemiausias 18 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Innoviva Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Innoviva Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

151 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.